Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mehmet Asim Bilen"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In this review, we aim to provide a comprehensive assessment of the evolving landscape of the perioperative management in renal cell carcinoma (RCC), emphasizing its dynamic and intricate nature. We explore academic and clinical insights into the per
Externí odkaz:
https://doaj.org/article/f69fa3ef76bc489793bc0fd865c1b941
Autor:
Dattatraya Patil, Vikram M. Narayan, Reza Nabavizadeh, Milton Williams, Dylan J. Martini, Kenneth Ogan, Shreyas S. Joshi, Sean Steele, Michelle I. Higgins, Viraj A. Master, Aarti Sekhar, Mehmet Asim Bilen, Sarah P. Psutka
Publikováno v:
Cancer. 127:1974-1983
Background Body composition and inflammation are gaining importance for prognostication in cancer. This study investigated the individual and combined utility of the preoperative skeletal muscle index (SMI) and the modified Glasgow Prognostic Score (
Autor:
Dylan J. Martini, Michelle I. Higgins, Sarah P. Psutka, Sean Steele, Aarti Sekhar, Mehmet Asim Bilen, Benjamin Petrinec, Viraj A. Master, Dattatraya Patil, Sean Evans
Publikováno v:
European journal of radiology. 132
Purpose Body composition measures provide valuable information for prognostication and treatment election in cancer patients. We investigated the novel use of magnetic resonance imaging (MRI) for skeletal muscle and adipose tissue cross-sectional are
Autor:
Bradley Alexander McGregor, Hannah Dzimitrowicz, Rana R. McKay, Marina D. Kaymakcalan, Akram Mesleh Shayeb, Nazli Dizman, Tian Zhang, Toni K. Choueiri, Danielle Urman, Daniel Y.C. Heng, Sumanta K. Pal, Akhilesh Sivakumar, Xin Gao, Pedro C. Barata, Luis Meza, Mehmet Asim Bilen, Chun Loo Gan
Publikováno v:
Journal of Clinical Oncology. 39:291-291
291 Background: Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. Despite cabo improving RCC outcomes, VTE management in these patients remains a challenge, partly due to poor understanding of cabo safety prof
Autor:
Balaji Venugopal, Toni K. Choueiri, A. di Pietro, Laurence Albiges, Hideaki Miyake, Aleksander Chudnovsky, Paul B. Robbins, Bo Huang, G. Gravis, Keith A. Ching, Mehmet Asim Bilen, J.M.G. Larkin, Mariangela Mariani, Boris Alekseev, Robert J. Motzer, Sumanta K. Pal
Publikováno v:
Annals of Oncology. 30:v361
Autor:
Kenneth Ogan, Greta Russler, Bradley C. Carthon, Yuan Liu, Dylan J. Martini, Viraj A. Master, Julie M. Shabto, Wayne Harris, Alexandra Speak, Elise Hitron, Mehmet Asim Bilen, Sarah Caulfield, Omer Kucuk
Publikováno v:
Journal of Clinical Oncology. 37:613-613
613 Background: BMI has been explored as a prognostic factor in cancer pts and treatment-related toxicities have been associated with responses to VEGF-targeted therapy in mRCC pts. We investigated the association of BMI and adverse events (AEs) and
Autor:
Bradley C. Carthon, Kenneth Ogan, Yuan Liu, Alexandra Speak, Wayne Harris, Sarah Caulfield, Elise Hitron, Greta Russler, Omer Kucuk, Julie M. Shabto, Mehmet Asim Bilen, Viraj A. Master, Dylan J. Martini
Publikováno v:
Journal of Clinical Oncology. 37:612-612
612 Background: Ratios of neutrophils, monocytes, and platelets to lymphocytes (NLR, MLR, and PLR) are associated with poor CO in cancer pts. We investigated the association of NLR, MLR, and PLR and CO in mRCC pts treated with cabo. Methods: We perfo
Autor:
Haydn T. Kissick, Jennifer W Carlisle, Fares Hosseinzadeh, Kyu Seo Kim, Mehmet Asim Bilen, Caroline S. Jansen, Viraj A. Master, Kevin Richard Melnick, Nataliya Prokhnevska, Amir Ishaq Khan
Publikováno v:
Journal of Clinical Oncology. 36:673-673
673 Background: Renal cell carcinoma (RCC) has been shown to be a genetically and morphologically heterogeneous cancer. As studies show the significance of tumor-infiltrating lymphocytes (TIL) in cancer, it is critical to examine how the phenotype of
Autor:
Mehmet Asim Bilen, Nizar M. Tannir, Eric Jonasch, Cihan Duran, Matthew T. Campbell, Emre Altinmakas, Zita Dubauskas Lim
Publikováno v:
Journal of Clinical Oncology. 35:478-478
478 Background: Cabozantinib (C) prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on first-line VEGFR-TKI. No standard of care systemic therapy exis
Autor:
Manal Tabba, Daniel Canter, Omer Kucuk, Mehmet Asim Bilen, Bradley C. Carthon, Carla LaShannon Ellis, Viraj A. Master, Wayne Harris
Publikováno v:
Journal of Clinical Oncology. 35:523-523
523 Background: Despite many therapeutic advances, Renal Cell Carcinoma (RCC) still is a leading cause of cancer morbidity and mortality. A recent phase 2 study has examined the combination of Sunitinib and Gemcitabine in a poor risk RCC trial popula